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ABSTRACT 
Background  
In medicine, algorithms can inform treatment decisions by combining the most up-to-date evidence 
about side-effect profiles of medications which are comparable in efficacy. Their use provides 
opportunities for improved shared clinician-patient decision-making when initiating therapy. We 
designed a decision support tool that incorporated the latest evidence regarding antipsychotic side-
effects. The tool allowed patients to select one side-effect commonly associated with antipsychotics 
that they wished to avoid; the tool then provided a list of suggested medications and ones to avoid.  
Objective 
To explore qualitatively the acceptability and usefulness of the decision support tool from the 
perspectives of patients and psychiatrists. 
Methods 
This qualitative study took place at a mental health and community hospital in Oxford, United 
Kingdom, in 2018. Four patients/carers and four psychiatrists were recruited to two focus groups to 
explore their perceptions of the tool. Data was thematically analysed.  
Findings 
Findings demonstrated a high degree of acceptability and potential usability of the decision support 
tool for patients and psychiatrists. The main themes to emerge relating to the decision support tool 
were ‘prescribing preferences and practices’, ‘consideration and awareness of side-effects’, ‘app 
content, layout and accessibility’, ‘influence on clinical practice’ and ‘role in decision-making’. 
Conclusions 
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A proof-of-concept clinical study will incorporate the recommendations produced from the findings 
into the tool’s design.  
Clinical Implications 
Digital decision support tools provide opportunities for the most up-to-date information on 
medication side-effects to be used as the basis for shared clinician-patient decision making. This tool 
has the potential to improve adherence to psychiatric medication, with benefits to clinical outcomes 
and healthcare resourcing.  
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BACKGROUND  
The global prevalence and burden of psychiatric disorders worldwide is rising, yet this is not 
reflected by the slow pace of progress in treatment development[1]. It is imperative that all available 
scientific information is considered when making treatment decisions to improve patient outcomes 
and clinical care. Precision medicine provides patients with customised interventions that are likely 
to be effective, whilst having tolerable side-effect profiles[2], often informed through the 
development of medical algorithms[3]. Decision support tools (DSTs) are innovative technologies 
that can provide continuously updated information about medications to promote shared decision-
making between patients and clinicians[4].  
DSTs have the potential to improve adherence to medical therapies through patient decision-
making, empowerment and improved awareness of potential side-effects[5]. Negative experiences 
of side-effects are a major reason for treatment discontinuation among patients, with up to 50% of 
patients reporting this as a reason for non-compliance[6]. In addition, having past experience of 
side-effects can lead to an aversion to future medications, including antipsychotics, resulting in 
poorer adherence[7].  
Studies using non-digital DSTs that aim to improve shared decision-making in antipsychotic 
prescribing have demonstrated improved perceived involvement and disease knowledge, which is 
associated with better clinical outcomes[8]. However, a key feature missing in existing treatment 
algorithms is their ability to dynamically incorporate patients’ views in the decision-making process. 
We wanted to fill this gap and create a more intuitive, patient-friendly and web-based application 
for comparing antipsychotics in terms of their likelihood of causing specific side effects.  
Our DST 
Our computer-based DST, “In Control of Effects”, was developed by RStudio v.1.1.463[9] using the 
package Shiny[10]. The production version of the application is hosted on a Ubuntu 16.0.4.4 x 64 
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server using Shiny Server Open Source (v.1.5.9.923). The DST is an application, which is structured 
into three screens: instructions, side-effect selection and results (Figures 1a&b). The user navigates 
between the individual pages using a series of clicks. The initial section presents instructions for 
using the application and emphasizes that the purpose of the DST is to act as a decision support tool 
only in the context of a discussion between the patient and the treating clinician. In the second 
section, participants are presented with four side effects (weight gain, sexual dysfunction, irregular 
heartbeat and stiffness/tremor) and are asked to select one side-effect they would like to avoid. The 
side effects were chosen on the basis of data availability from a recent meta-analysis [11]. Each side-
effect is accompanied by a short explanation of that side-effect in lay language, which can be 
accessed by tapping or clicking a toggle to reveal content. When a participant submits their 
responses, they are led to the results section and are shown a list of the top three medication 
recommendations, as well as the top three antipsychotics to avoid. 
The database used to rank the antipsychotics in terms of specific side-effects was based on the 
results of a network meta-analysis of published and unpublished randomised controlled trials [12]. 
User input was coded as binary (0 = not selected, 1 = selected), and then used to generate a new 
score per medication by averaging the prevalence of the side-effects per drug weighted to the 
preferences of the participant. A lower score indicates a decreased likelihood of experiencing the 
side-effects selected (i.e. more favourable) relative to the other antipsychotics in the dataset, 
whereas drugs with a high score have an increased risk of producing the side-effect. 
In this study we aimed to qualitatively explore the acceptability and usefulness of the DST from the 
perspectives of patients, carers and psychiatrists.  
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OBJECTIVE 
We aimed to explore psychiatrist, patient and carers’ views on the acceptability and usefulness of 
our newly developed DST in relation to its use as a shared decision-making tool between clinicians 
and patients. Our intention was to use the study findings to modify and make further improvements 
to the DST, before piloting it in a real-world clinical setting. 
 
METHODS 
Participants and setting 
Two focus groups took place at the Warneford Hospital, Oxford Health NHS Foundation Trust in 
Oxford, United Kingdom, between June and August 2018 (one focus group with psychiatrists and one 
with patients, to allow both user groups to speak freely without any reticence and to promote 
constructive discussions). Ethical approvals were not required due to the project being classed as 
Quality Improvement by Oxford Health NHS Foundation Trust; however written informed consent 
was taken from each participant prior to their participation.  
The focus groups aimed to identify how acceptable the DST was to psychiatrists, patients and carers 
in terms of its layout, content and applicability to the clinical setting. Focus groups were deemed 
more appropriate than individual interviews as they enabled collective discussion and debate 
between users with multiple perspectives.  
 
Access, Recruitment and Sampling 
Psychiatrists were recruited to the first focus group through the Thames Valley Higher Trainee in 
General Adult and Old Age Psychiatry Forum. Those who expressed an interest in participating were 
provided with a participant information sheet via email and were asked to contact the researchers.  
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The second focus group was undertaken with patients and carers, who were identified via the 
Patient and Public Involvement Lead for Oxford Health NHS Foundation Trust, who posted an 
advertisement for the focus group via a number of forums including local patient and public 
involvement groups, Trust intranet, patient/research websites, social media outlets and through 
local mental health partnerships and charities. To be eligible for study inclusion participants - 
whether patients or carers - had to have had a mental health diagnosis requiring treatment with an 
antipsychotic (currently or in the past).  
A convenience sampling strategy was implemented for both focus groups (i.e. all those able to 
attend were invited). Information and guidance to run the focus groups were found on the Involve 
website[13]. The focus groups began with a researcher (LW) providing a short, interactive, visual 
demonstration of the DST, before answering questions relating to it. Each focus group lasted one 
hour and was informed by a topic guide that covered themes relating to the DST’s layout, content, 
applicability, usability and acceptability (Table 1). The focus groups were moderated and facilitated 
by at least two researchers from the team: CH and LW led the psychiatrists’ focus group, whilst CH, 
LW and IK led the patients/carers’ one.  Focus groups were digitally recorded and then transcribed 
by a local transcription service. All identifying participant details were anonymised during 
transcription and the focus group recordings were destroyed. 
Table 1: Examples of questions from topic guide used to undertake focus groups with psychiatrists and patients/carers 
 
• Can you tell me what you think about the layout of the DST?  
• Can you tell me what you like/do not like about the DST? 
• Can you think of any ways the DST could be improved upon (structure, format etc..)? 
• Can you think of anything that should be added/removed to the app to improve it? 
• Are you aware of any other example of electronic decision-making tools? 
 
Specific to psychiatrists 
• What are the strengths and weaknesses of using this app in clinical practice? 
• Do you think the DST may have any impact on the doctor-patient relationship (i.e. too 
lengthy in set up, or too impersonal)? 
• Are there any particular patient groups or circumstances where this tool can be particularly 
useful (or unhelpful)? 
• Are there any advantages/disadvantages of using this DST in clinical practice? 
• Are there any “links/shortcuts” that you would like to have on your iPad/computer, when 
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using the app (such as a link to the BNF, or a list of contraindication/interactions)? 
• How do you feel using an electronic tool compares to using more traditional methods in 
clinics (e.g. book-based guidelines)? 
 
Specific to patients/carers 
• Are there any advantages/disadvantages of using this DST in your clinic appointment? 
• How do you think other patients and carers will respond to the DST?  
• Do you think it may have any impact on your relationship with the doctor (i.e. too lengthy in 
set up, or too impersonal)? 
• How do you feel when your doctor would use an electronic tool compared to using more 
traditional methods, such as a book, in your clinic appointment? 
 
 
Data Analysis 
Data was thematically analysed and managed using the Framework approach[14]. This approach 
allows qualitative data to be analysed flexibly and systematically, as data is entered into a grid matrix 
that allows researchers to review data within and across participants[14]. A researcher (CH) coded 
the transcripts and, using the constant comparative method to iteratively compare new findings 
with existing findings as they emerged from the dataset[15], any similarities and differences in 
perspectives between psychiatrists and patients/carers were established. Transcript data were 
inserted into a Framework matrix to enable data ordering and synthesis[14]; this enabled within and 
across case data analysis from both focus groups. Through this process, relevant themes pertaining 
to participants’ views and perspectives on the DST emerged from the dataset. These emerging 
themes were discussed within the research team (CH, LW, IK) as a method of triangulation to verify 
the study findings. 
 
FINDINGS 
Summary of Main Themes 
Eight participants attended the focus groups (four psychiatrists and four patients/carers). The four 
psychiatrists were relatively young (mean age: 38 years, range 30-45) and had been practicing 
clinically for eight years on average. They all regularly treated inpatients and outpatients who 
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needed antipsychotics prescribing. The average age of the patients/carers was 60 years (range 53-
67). Patients/carers had a range of mental health diagnoses, including bipolar disorder, anxiety and 
depression, and all had experience of taking, or caring for someone taking, antipsychotic medication. 
Summary characteristics are presented in Table 2. The main themes to emerge from the dataset 
about the DST were ‘prescribing preferences and practices’, ‘consideration and awareness of side-
effects’, ‘app content, layout and accessibility’, ‘influence on clinical practice’ and ‘role in decision-
making’.  
Table 2: Summary characteristics of psychiatrists and patients/carers 
 Psychiatrist 
n=4 
 Patients/Carers 
n=4 
Age (years) 38 ± 7 
 
Age (years) 59.5 ± 6.1 
 
Years in practice 7.75 ± 2.9 
 
Experience with 
antipsychotic medication 
- Currently taking 
- Taken in the past 
- Carer  
 
 
1 
21 
21 
Approximate number 
of patients seen each 
month in clinical 
practice who need 
antipsychotic 
medication 
11 ± 6 
 
Diagnosis 
- Depression 
- Bipolar disorder 
 
2 
1 
  Medication taken Amitriptyline, 
Stemetil, 
Chlorpromazine, 
Trifluoperazine, 
Halopirdo 
 
1One person fulfils the criteria of both groups.  
 
Prescribing preferences and practices 
All psychiatrists commented that the DST would help increase their awareness and consideration of 
a wide scope of medications. They felt this was necessary as they admitted that they generally 
prescribed a limited selection of drugs, based on anecdotal evidence and simplistic cost-
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effectiveness considerations. However, a lack of familiarity with some of the DST’s recommended 
medications, and the fact that some were not licensed for use, provided a deterrent.  
‘Bar Loxapine, which I’ve seen once, I’ve never seen any of the others…That would not be helpful for 
me.’ Psychiatrist 2 
 
Patients and carers commented that the DST could provide a useful starting point for discussions 
with their doctor about medication preferences, as it ranked medications in terms of suitability to 
their own preferences.  
‘I want to have the greatest chance of success on proven clinical stuff so far…But number one would 
be the one to start with...If it didn’t work, then try number two.’ Patient/carer 1 
 
Psychiatrists felt that the comprehensive, up to date and evidence-based information on the DST 
would increase their prescribing confidence with new medications.  However, contextual factors 
relating to patients’ physical and social health, were noted as also influencing psychiatrists’ 
prescribing practices, something which was not factored for by the DST. Despite this, psychiatrists 
felt that it could be a useful base for considering medication options with patients. 
‘You’re much more constrained in the antipsychotic you could give each patient…But it could still be 
used as a launch pad for those types of discussions.’ Psychiatrist 4 
 
Consideration and awareness of side-effects 
Psychiatrists commented that doctors often make prescribing choices based on efficacy, without 
considering sufficiently the impact of potential side-effects. Conversely, patients/carers stated that a 
11 
 
drug’s side-effect profile would substantially influence their likelihood of compliance and that this 
information was crucial. All participants felt that information relating to a patient’s age and co-
morbidities on drug efficacy, mode and frequency of administration and potential side-effect 
severity should be included within DST. They also felt it should provide a balanced level of 
information on the most common side-effects of each drug listed, to allow patients to decide how 
acceptable these side-effects were. 
‘[Otherwise] you’d be selecting a drug without necessarily thinking about what the other side-effects 
could be…And then you get prescribed one that actually has another side-effect that you don’t want 
at all, but it wasn’t even mentioned.’ Patient/Carer 1 
 
Patients/carers felt that receiving information about the likelihood of experiencing a side-effect and 
its subsequent severity would enable them to weigh up the risk versus benefit ratio, informing their 
decision-making.  
‘Weight gain in 3% of the population… You’d probably say, I’ll be okay with that even if you are 
already overweight. Whereas if it’s 50% of patients that use this put on weight, you’ll probably think, 
then I’m not so sure.’ Patient/Carer 1 
 
App content, layout and accessibility 
Visuals 
The DST was described as ‘attractive’ and ‘readable’ by most participants, with its blue and green 
features perceived as ‘healthcare colours’.  However, some visual design improvements were 
suggested, including incorporating the word ‘decision-aid’ into the name of the DST, increasing the 
font size, providing bite-size sections or drop-down lists of content and visually depicting the highest 
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ranked medications and their side effect profiles. Most participants wanted percentages displayed as 
they were easily understandable. 
‘I think everybody understands if you say 100%...Because if it was a 50% chance of weight gain, 
that’s a fair chance you’re getting it. It’s a toss of a coin. Whereas if it was just 10%, you might not, I 
suppose.’ Patient/Carer 1 
 
Interactivity 
All participants felt the tool was simple and straightforward to use, whether on a mobile or a laptop, 
and that it was easy to navigate. 
‘I’m all for simplicity and I found it… I’m a technophobe. I’ve got my smartphone. It’s not set up yet. 
But I used that smartphone with no problem at all.’ Patient/Carer 4 
 
The DST was seen as a means of stimulating, rather than replacing, discussion, avoiding paternalism 
by promoting shared decision-making between doctors and patients. However, a couple of 
psychiatrists felt the DST would be more accessible if it was downloadable, rather than requiring 
WiFi access. Most participants felt it would be most useful as an adjunct to other information 
sources such as the internet, leaflets and face-to-face discussions.  
‘It’s part of an armoury of enabling patients to be involved in their treatment decisions.’ Psychiatrist 
4 
 
One patient/carer suggested that a supplementary app website would be helpful, with patients 
being directed to it after their introduction to the DST during their consultation with their doctor. 
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‘If you’ve got it on a website…Having done it in the office with you… They can go away if they haven’t 
made the decision and play with it some more, which might be useful.’ Patient/Carer 4 
 
Influence on clinical practice 
All psychiatrists felt that the DST could be utilised clinically, both in cases of first-episode psychosis 
and for long-term service-users, as a monitoring and review tool. They felt that the more they used 
the DST, the more likely it would be to change their clinical practice.  
‘I imagine that if it is something that is very routinely used … I’d like to think somebody like me would 
make changes over time. Not within a week, two weeks, but maybe over a year.’ Psychiatrist 2 
 
Some psychiatrists felt there was a danger that the DST could increase paternalism if the drugs listed 
on it were not perceived as clinically relevant, as this could result in doctors overriding patient 
preferences if they felt that the patient’s drug of choice was not credible. However, others 
commented that it could help educate doctors about the efficacy and side-effect profile of relatively 
unknown medications, increasing the likelihood of them being integrated into practice.  
‘Certainly, there’s things there which I’m sure I’m going to learn that I will integrate into my practice 
as I go along. If there is a link for the evidence, that could be very helpful, actually, because every 
evidence needs to be looked at and can be discussed, debated, argued against.’ Psychiatrist 2 
 
Psychiatrists felt the DST was unsuitable for use in Primary Care as general practitioners may lack the 
knowledge or experience to prescribe antipsychotics. However, some patients/carers felt it could be 
used by general practitioners as a referral tool or to help monitor psychiatric patients in primary 
care, especially if patients were unable to see their psychiatrist immediately due to long waiting lists. 
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‘You’d see a doctor a lot quicker than you’d see a psychiatrist if you’re feeling awful. Wouldn’t you 
want to see your doctor pretty quickly for a potential change of drug that might assist you, rather 
than wait?’ Patient/Carer 1 
 
Role in decision-making 
All participants felt patients should be involved in decision-making around medication choices and 
that the DST promoted informed choice, patient engagement and discussion around potential trade-
offs between side-effect tolerability and drug efficacy. 
‘This fulfils, or could fulfil, a valuable purpose in getting a bit more buy-in to treatment from patients. 
Because the drug has come out of their preferences, and not you saying, you should go on this.’ 
Psychiatrist 4 
 
Regarding compliance, all psychiatrists felt that patients would be more likely to comply with their 
medications after engaging with the decision-making process via the DST. However, some 
patients/carers felt that regular face-to-face doctor/patient discussions were required to avoid 
patients feeling pressured into making decisions using the DST alone. All participants acknowledged 
the complexity of the decision-making process and felt the DST was a small piece of the whole 
picture. 
‘The app… It’s a good start…Sometimes decision-making is more complex. You as a clinician have to 
take more into consideration rather than just a few clicks, side effects’ Psychiatrist 1 
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DISCUSSION  
The focus group findings have demonstrated the potential of the DST to increase clinician and 
patient knowledge, confidence and awareness of a wide range of antipsychotics, as well as providing 
a forum for enhancing collaborative patient-clinician decision-making. However, a number of issues 
were identified, which, if addressed appropriately, could substantially improve the acceptability and 
credibility of the tool. 
The inclusion in the tool of any antipsychotic studied in a randomised controlled trial (either licensed 
or unlicensed, commissioned or non-commissioned) was viewed by psychiatrists’ as unnecessary and 
unhelpful. It is important therefore, that the list of recommended medications on the DST are 
carefully reviewed and adapted to ensure that only medications that are available in a specific 
clinical context are included[16]. This will serve to increase the usability, acceptability and relevance 
of the DST for both patients and clinicians, whilst avoiding potential disappointment or frustration 
that seemingly suitable medications are unattainable. 
Participants appreciated the DST’s ability to rank medications in terms of suitability, with regard to 
their side-effect profiles, but commented that they would like more information about the likelihood 
of experiencing a side-effect from one medication compared to another. This is something which 
warrants careful consideration when making further modifications to the DST[17]. Whilst the visual 
ranking of different drugs can be a useful discussion aid, care must be taken to ensure that the 
information on display is not misleading. For example, a lack of clarity around whether the data 
presented ranks drugs against one another or versus placebo is possible, as is confusion around 
whether the relative or absolute risk is being presented. This could lead to clinicians and patients 
selecting drugs based on evidence that has been misinterpreted, raising ethical issues around 
informed choice[18]. Care must be taken to ensure that the data are based on the best available 
evidence and presented in a transparent way, whilst remaining accessible and easily understandable 
to patients and clinicians alike[19].  
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In addition, in response to feedback from participants, the DST could be further modified to increase 
the number of side-effects displayed so as to provide patients with a realistic overview of the side-
effects they are most likely to encounter with different types of medications[20]. This is important, 
as whilst a patient may express a strong desire not to take a drug that leads to weight gain, if they 
see that this drug is more likely to cause a number of other side-effects than a slightly lower ranked 
(but still efficacious) drug, they may use this information to inform their decision-making, which may 
in turn affect their subsequent medication compliance. 
Any clinical tool should be accessible to the wider patient population and reflect the needs of a 
variety of patients, including those who are not technologically experienced. This can be achieved 
not only by ensuring that the information presented is as simple, understandable and easy to 
navigate as possible, but also by considering the provision of supplementary resources to 
complement the information provided. Our DST is intended to be used as an adjunct to, rather than 
a replacement for, face-to-face clinical discussions[21]. This message must be clearly conveyed to 
both patients and clinicians in order to avoid disappointment, communication errors or a breakdown 
in the clinician-patient relationship, all of which may lead to a reduction in compliance and an 
increase in patients’ dissatisfaction with care.  
 
CLINICAL IMPLICATIONS 
The DST improved participant involvement and knowledge about medications by demonstrating the 
advantages of a digital solution to guide clinical decision making in real world practice. There is a 
need for further modifications to be made to the tool to ensure that it meets the preferences and 
requirements of patients, carers and clinicians. Once these changes are complete, the newly 
modified DST will be tested in a pilot acceptability study in psychiatric outpatient settings across 
different geographical areas, to collect data on how patients and clinicians experience using the DST, 
17 
 
the subsequent impact on patient outcomes and to increase the generalisability of the findings. In 
addition to enhancing informed choice for patients, improving patient-clinician communication and 
ensuring that clinical prescribing practices in psychiatry are consistent, the digital platform can 
provide a cost-effective solution to aligning the provided advice with the latest available 
evidence[22]. This will be an important step in the field of precision medicine in clinical psychiatry.  
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